SC-514 - CAS# 354812-17-2 Catalog No.:M6663-2 33) was higher than that

33) was higher than that of buspirone (pKi

and in vivo active LRRK2 kinase inhibitor

Currently it is in Phase II/III clinical trials for Hodgkin's lymphoma and advanced breast cancer

PubMed PMID: 24660890

Ferrer-Torres D

SC-514 - CAS# 354812-17-2 Catalog No.:M6663-2 33) was higher than thatSC 514, CAS No. 354812 17 2, is a selective and reversible inhibitor of IB kinase 2 (IKK2) that may target osteoclastogenesis. SC 514 dose dependently inhibits RANKL induced osteoclastogenesis and induced apoptosis and caspase 3 activation in RAW264. 7 cells. Targeting IKK by SC 514 may be a potential treatment for osteoclast related disorders such as osteoporosis and cancer induced bone loss. Product information CAS Number: 354812 17 2 Molecular